Roche (RAS) and Axiogenesis have entered into an agreement for the development and distribution for the Cor.At 100 per cent pure cardiomyocytes platform as an integral part of the Xcelligence system.
Under the terms of the agreement, RAS will market cell-systems based on the technology of the Axiogenesis Cor.At, customised for the Xcelligence platform.
The Roche Xcelligence system is designed for applications spanning from short-term kinetic analysis - for example, measuring effects on G-protein coupled receptors (GPCRs) - to assays for cell proliferation and cytotoxicity.
The Cor.At cells from Axiogenesis form an ideal couple to merge the latter qualities to the next level.
The cells are quality-controlled, storable and available under GMP-conditions and resemble a physiologically normal phenotype of either neonate or an adult heart.
This couple, therefore, enables research studies focussing on long-term life behaviour of cardiac cells in vitro.
'We are convinced that the Axiogensis cell and technology portfolio will lead to products for cell-based assays to strengthen our industrial standard for life science cell analysis in the future,' said Manfred Baier, head of Roche Applied Science.
Dr Heribert Bohlen, founder and chief executive officer of Axiogenesis, expects that the major advantages of the technology of the Xcelligence system over conventional approaches will benefit from the Axiogenesis cell portfolio.
'The system detects any number of cellular parameters such as attachment, spreading, growth, death and specific morphological changes, simply and reliably,' he said.
